Cardiac Glycosides Increase Temozolomide Anticancer Activity in Therapy Resistant Glioblastoma Cells
Glioblastomas (GBMs) are a form of malignant gliomas characterized by a dismal prognosis. Standard treatment for glioblastoma patients is combined maximal surgical removal of the tumor with postoperative radiotherapy and concomitant chemotherapy with Temozolomide (TMZ). Among the histological charac...
Main Authors: | Anisha Valluri, Logan Lawrence, Krista L. Denning, Jonathan Cuda, Guo-Zhang Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | International Journal of Translational Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-8937/2/2/12 |
Similar Items
-
Cardiac Glycosides in Human Physiology and Disease: Update for Entomologists
by: Rif S. El-Mallakh, et al.
Published: (2019-04-01) -
Studies of the clinical pharmacology of cardiac glycosides
by: Aronson, J
Published: (1977) -
Na<sup>+</sup>/K<sup>+</sup>-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation
by: Jiří Bejček, et al.
Published: (2021-03-01) -
Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
by: Wenjie Qin, et al.
Published: (2024-09-01) -
Antidote use for cardiac arrest or hemodynamic instability due to cardiac glycoside poisoning: A narrative review
by: Jessie Beaulieu, et al.
Published: (2024-09-01)